December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

273.84 USD -2.00 (-0.73%)
Official Closing Price Updated: 7:39 PM EST, Jan 19, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biogen, Inc.

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
57 58 Next >
Biogen Reports Quarterly Revenues of $3.1 Billion
Biogen Inc. (Nasdaq: BIIB) today reported first quarter 2018 financial results, including: 
From Business Wire News Releases
New SPINRAZA® (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants
New SPINRAZA® (nusinersen) Data Unveiled at AAN Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants 
From Business Wire News Releases
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases 
From Business Wire News Releases
Biogen Builds on Its 40-Year Legacy in Neuroscience with Presentation of Research from Its Portfolio of Medicines and Investigational Programs for Neurodegenerative Diseases
Biogen Builds on its 40-Year Legacy in Neuroscience with Presentation of Research From its Portfolio of Medicines and Investigational Programs 
From Business Wire News Releases
Factors of Influence in 2018, Key Indicators and Opportunity within McDonald's, Biogen, Freeport-McMoRan, Community Health, Enphase Energy, and Exxon Mobil — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of McDonald's Corporation... 
From GlobeNewswire News Releases
Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe
Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe 
From Business Wire News Releases
Biogen to Report First Quarter 2018 Financial Results on April 24, 2018
Biogen to Report First Quarter 2018 Financial Results on April 24, 2018 
From Business Wire News Releases
Biotechnology Companies with Great Potential
From PR Newswire
Healthcare Veterans Launch Martin Pharmaceuticals to Repurpose Drugs for Orphan Indications; Seed Round Oversubscribed
Two accomplished healthcare executives, David Martin Geliebter and Sven Martin Jacobson, founders of Remedy Pharmaceuticals, announced the launch of Martin Pharmaceuticals, with the mission of... 
From Business Wire News Releases
Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting
Biogen (Nasdaq: BIIB) will present data from its portfolio of investigational therapies for people with neurodegenerative diseases at the Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD)... 
From Business Wire News Releases
Biogen to Present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Advances in Alzheimer’s and Parkinson’s Therapies, an AAT-AD/PD Focus Meeting. A plenary session titled “The Importance of Early... 
From Business Wire News Releases
Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
BIOGEN TO ACQUIRE FROM PFIZER FIRST-IN-CLASS PHASE 2b READY ASSET FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA 
From Business Wire News Releases
New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen)
New Data Presented at MDA Clinical Conference Show Benefit in Motor Function for Infants, Teens and Young Adults Treated With SPINRAZA® (nusinersen) 
From Business Wire News Releases
Fake News Attack Against Ampio Pharmaceuticals (NASDAQ: AMPE) Starting to Unravel as Suitors Line Up
Tags business/economy c:canada sports/fitness/recreation
From EIN Presswire
Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis
Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis 
From Business Wire News Releases
Biogen to Present at the Cowen and Company 38th Annual Health Care Conference
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Cowen and Company 38th Annual Health Care Conference. The webcast will be live on Monday, March 12, 2018 at 3:30 p.m. ET. To... 
From Business Wire News Releases
The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy 
From Business Wire News Releases
Biogen Reports Top-Line Results from Phase 2b Study of Natalizumab in Acute Ischemic Stroke
Biogen reports topline results from Phase 2b study of natalizumab in acute ischemic stroke 
From Business Wire News Releases
Biogen to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Leerink Partners 7th Annual Global Healthcare Conference. The webcast will be live on Wednesday, February 14, 2018 at 1:30 p.m.... 
From Business Wire News Releases
Consolidated Research: 2018 Summary Expectations for Kimball Electronics, Madrigal Pharmaceuticals, American Railcar Industries, H&R Block, Biogen, and Equinix — Fundamental Analysis, Key Performance
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kimball Electronics, Inc.... 
From GlobeNewswire News Releases
This Morning's Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and Biogen
From PR Newswire
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively 
From Business Wire News Releases
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018- Updated Call Timing
BIOGEN TO REPORT FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS ON JANUARY 25, 2018- UPDATED CALL TIMING 
From Business Wire News Releases
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint
Adaptive Phase II Study of BAN2401 in Early Alzheimer’s Disease Continues toward 18-Month Endpoint 
From Business Wire News Releases
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018 
From Business Wire News Releases
Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY 
From Business Wire News Releases
Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference
Biogen to Present at the 36th Annual J.P. Morgan Healthcare Conference 
From Business Wire News Releases
Stock Review for Biotech's Investors -- Bioverativ, ACADIA Pharma, Inovio Pharma, and Biogen
From PR Newswire
Biogen to Present at the Guggenheim 5th Annual Healthcare Conference
Biogen to Present at the Guggenheim 5th Annual Healthcare Conference 
From Business Wire News Releases
Biogen Appoints Mark Hernon as SVP, Chief Information Officer
Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior Vice President, Chief Information Officer, effective December 4. 
From Business Wire News Releases
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
57 58 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.